Financial results are lacking, but the growth story looks highly intact as Red Cat has shared promising developments. See why I rate RCAT stock a hold.
Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...